This is a preview of subscription content, log in via an institution to check access.
Notes
2014 euros
Reference
Fust K, et al. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. PharmacoEconomics : 7 Dec 2016. Available from: URL: http://doi.org/10.1007/s40273-016-0474-0
Rights and permissions
About this article
Cite this article
Pegfilgrastim cost effective for preventing febrile neutropenia. PharmacoEcon Outcomes News 769, 25 (2017). https://doi.org/10.1007/s40274-017-3661-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3661-0